Retrospective analysis on efficacy of convalescent plasma in acute respiratory distress syndrome due to COVID-19

Autores

Palavras-chave:

COVID-19, Respiratory distress syndrome, COVID-19 serotherapy [supplementary concept]

Resumo

BACKGROUND: Coronavirus disease 2019 (COVID-19) is an ongoing global health threat. However, currently, no standard therapy has been approved for the disease. OBJECTIVES: To evaluate the clinical effectiveness of convalescent plasma (CP) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19. DESIGN AND SETTING: Retrospective study conducted at Kayseri City Education and Research Hospital, Kayseri, Turkey. METHODS: The case group consisted of adult patients (> 18 years) with ARDS due to COVID-19 who received CP in combination with antiviral and supportive treatment. These patients were compared with others who only received antiviral and supportive treatment. RESULTS: During the study period, a total of 30 patients with ARDS due to COVID-19 were included. Eleven patients (36%) received CP in combination with antiviral and supportive treatment, whereas nineteen patients (64%) in the control group only received antiviral and supportive treatment. On admission, the median age, demographic and clinical data and initial laboratory test results were similar between the groups (P > 0.05). On the 14th day of treatment, the laboratory values remained similar between the groups (P > 0.05). The mortality rates were not significantly different between the groups. CONCLUSION: CP treatment did not affect mortality or lead to clinical improvement for COVID-19 patients with ARDS.

Downloads

Não há dados estatísticos.

Biografia do Autor

Esma Eren, Kayseri City Education and Research Hospital

MD. Physician, Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Turkey.

Ayşegül Ulu Kılıç, Kayseri City Education and Research Hospital

MD, PhD. Professor, Department of Infectious Disease and Clinical Microbiology, Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Turkey.

Serdal Korkmaz, Kayseri City Education and Research Hospital

MD, PhD. Assistant Professor, Department of Hematology, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Turkey.

Merve Yıldız, Kayseri City Education and Research Hospital

MD. Physician, Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Turkey.

Recep Civan Yüksel, Kayseri City Education and Research Hospital

MD. Physician, Intensive Care Unit, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Turkey.

Ayşin Kılınç Toker, Kayseri City Education and Research Hospital

MD. Physician, Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Turkey.

Emine Arman Fırat, Kayseri City Education and Research Hospital

VIIMD. Physician, Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Turkey.

Zehra Bestepe Dursun, Kayseri City Education and Research Hospital

MD. Physician, Department of Infectious Disease and Clinical Microbiology, Kayseri City Education and Research Hospital, Kayseri, Turkey.

Ilhami Çelik, Kayseri City Education and Research Hospital

MD, PhD. Professor, Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Turkey.

Referências

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-

PMID: 32123347; https://doi.org/10.1038/s41564-020-0695-z.

Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Bio-medica: Atenei Parmensis. 2020;91(1):157-60. PMID: 32191675; https://doi.org/10.23750/abm.v91i1.9397.

World Health Organization (WHO). Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed in 2021 (May 13).

Ghareeb DA, Saleh SR, Nofal MS, et al. Potential therapeutic and pharmacological strategies for SARS-CoV2. J Pharm Investig. 2021:1-

PMID: 33688448; https://doi.org/10.1007/s40005-021-00520-4.

Özdemir Ö, Arsoy HEM. Convalescent (Immune) plasma therapy with all aspects: yesterday, today and COVID-19. Erciyes Med J. 2020;42(3):252-9. https://doi.org/10.14744/etd.2020.36528.

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90. PMID: 25030060; https://doi.org/10.1093/infdis/jiu396.

Sayinalp B, Çinar OE, Haznedaroğlu İC. Perspectives for immune plasma treatment of COVID-19. Turk J Med Sci. 2021;51(1):1-9. PMID: 32718128; https://doi.org/10.3906/sag-2005-410.

Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890-901. PMID: 32293713; https://doi.org/10.1002/jmv.25882.

Ahn JY, Sohn Y, Lee SH, et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020;35(14):e149. PMID: 32281317; https://doi.org/10.3346/jkms.2020.35.e149.

Klassen SA, Senefeld JW, Johnson PW, et al. Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv [Preprint]. 2020:2020.07.29.20162917. PMID: 33140056; https://doi.org/10.1101 /2020.07.29.20162917.

Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021;325(12):1185-95. PMID: 33635310; https://doi.org/10.1001/jama.2021.2747.

ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-33. PMID: 22797452; https://doi.org/10.1001/jama.2012.5669.

T.C. Sağlık Bakanlığı. Sağlik Hizmetleri Genel Müdürlüğü. Kan ve Kan Ürünleri Dairesi Başkanlığı. COVİD-19 İmmün (konvalesan) Plazma Tedarik ve Klinik Kullanım Rehberi. Ankara, Türkiye: T.C. Sağlık Bakanlığı; 2020. Available from: https://ekmud.org.tr/files/uploads/files/covid-19-immun%20plazma%20 rehberi-v5-26_10_2020.pdf. Accessed in 2021 (Jun 7).

Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020;26(11):1708-13. PMID: 32934372; https://doi.org/10.1038/s41591-020-1088-9.

Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020;105(12):2834-40. PMID: 33256382; https://doi.org/10.3324/haematol.2020.261784.

Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(5):460-70. PMID: 32492084; https://doi.org/10.1001/jama.2020.10044. Erratum in: JAMA. 2020;324(5):519.

Gharbharan A, Jordans CCE, Geurtsvankessel C, et al. Convalescent plasma for COVID-19. A randomized trial. medRxiv. 2020. https://doi.org/10.1101/2020.07.01.20139857.

Downloads

Publicado

2022-06-01

Como Citar

1.
Eren E, Kılıç AU, Korkmaz S, Yıldız M, Yüksel RC, Toker AK, Fırat EA, Dursun ZB, Çelik I. Retrospective analysis on efficacy of convalescent plasma in acute respiratory distress syndrome due to COVID-19. Sao Paulo Med J [Internet]. 1º de junho de 2022 [citado 14º de março de 2025];140(1):1-5. Disponível em: https://periodicosapm.emnuvens.com.br/spmj/article/view/675

Edição

Seção

Artigo Original